Navicixizumab (OMP-305B83) is a bispecific anti- VEGF and anti- DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer [1
CAS Number:
[1638338-43-8]
* VAT and and shipping costs not included. Errors and price changes excepted